文献速递白血病淋巴瘤

靶向细胞内癌蛋白WT1的CAR-T细胞抗肿瘤活性可通过疫苗增强

Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
PubMed 文献 · Blood · 2018-07-25

本研究开发了靶向WT1 235-243/HLA-A*2402复合物的CAR-T细胞,在异种移植模型中显示疗效,且经负载相应抗原的树突状细胞疫苗增强,该增强至少部分由CAR-T细胞扩增和激活介导。

要点

  • 靶向WT1 235-243/HLA-A*2402的CAR-T细胞在异种移植模型中显示抗肿瘤活性。
  • 负载相应抗原的树突状细胞疫苗可增强CAR-T细胞疗效。
  • 增强效应至少部分由CAR-T细胞扩增和激活介导。

核心结论

  • 靶向WT1 235-243/HLA-A*2402的CAR-T细胞在异种移植模型中显示疗效,且该疗效可被负载相应抗原的树突状细胞疫苗增强。

研究设计与样本

  • 研究开发了由靶向WT1 235-243/HLA-A*2402复合物的单链可变片段(scFv)组成的CAR-T细胞,并在异种移植模型中评估其疗效。

主要发现

  • CAR-T细胞在异种移植模型中显示疗效,经负载相应抗原的树突状细胞疫苗增强。
  • 增强的疗效至少部分由CAR-T细胞扩增和激活介导。

临床怎么用

  • 作者提供概念验证:靶向肽/主要组织相容性复合物的CAR-T细胞疗效可通过疫苗增强。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent success of chimeric antigen receptor (CAR)-T cell therapy for treatment of hematologic malignancies supports further development of treatments for both liquid and solid tumors. However, expansion of CAR-T cell therapy is limited by the availability of surface antigens specific for the tumor while sparing normal cells. There is a rich diversity of tumor antigens from intracellularly expressed proteins that current and conventional CAR-T cells are unable to target. Furthermore, adoptively transferred T cells often suffer from exhaustion and insufficient expansion, in part, because of the immunosuppressive mechanisms operating in tumor-bearing hosts. Therefore, it is necessary to develop means to further activate and expand those CAR-T cells in vivo. The Wilms tumor 1 (WT1) is an intracellular oncogenic transcription factor that is an attractive target for cancer immunotherapy because of its overexpression in a wide range of leukemias and solid tumors, and a low level of expression in normal adult tissues. In the present study, we developed CAR-T cells consisting of a single chain variable fragment (scFv) specific to the WT1235-243/HLA-A*2402 complex. The therapeutic efficacy of our CAR-T cells was demonstrated in a xenograft model, which was further enhanced by vaccination with dendritic cells (DCs) loaded with the corresponding antigen. This enhanced efficacy was mediated, at least partly, by the expansion and activation of CAR-T cells. CAR-T cells shown in the present study not only demonstrate the potential to expand the range of targets available to CAR-T cells, but also provide a proof of concept that efficacy of CAR-T cells targeting peptide/major histocompatibility complex can be boosted by vaccination.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Akahori Y, Wang L, Yoneyama M, et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood. 2018. PMID: 30045840. doi:10.1182/blood-2017-08-802926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。